RxDoctor Payments Data

Krishna Patel

Family · Alexandria, VANPI 1700391539

Payments from drug & device makers

$7,606in general payments, 2019–2025

Across 316 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$953
  • Novartis$812
  • Merck$731
  • Boehringer Ingelheim$701
  • Amgen$638
  • AstraZeneca$555
  • plus $3K from 14 others

What the payments were for

  • Food & beverage$7,33296%
  • Education$2734%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,606 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$114,757
EntrestoSacubitril/Valsartan37$67,451
FarxigaDapagliflozin Propanediol47$65,427
OzempicSemaglutide56$58,545
XareltoRivaroxaban36$50,659
EliquisApixaban35$35,359
VascepaIcosapent Ethyl41$30,574
Repatha SureclickEvolocumab17$25,313
Repatha SyringeEvolocumab14$21,205
Carvedilol157$1,588
Atorvastatin Calcium116$1,425
Metoprolol Succinate100$1,202
Amlodipine Besylate133$1,076
Rosuvastatin Calcium42$938
Ranolazine ErRanolazine14$767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$701$114,75784 claims
NovartisEntresto$812$67,45137 claims
AstraZenecaFarxiga$555$65,42747 claims
Novo NordiskOzempic$50$58,54556 claims
Johnson & JohnsonXarelto$953$50,65936 claims
PfizerEliquis$315$35,35935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →